{"id":"https://openalex.org/W2803772575","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","title":"Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098)","display_name":"Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098)","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2803772575","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","mag":"2803772575"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.90.15_supplement.p4.098","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112019089","display_name":"Bert B. Vargas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bert Vargas","raw_affiliation_strings":["UT Southwestern Clinical Center Richardson/Plano Richardson TX United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern Clinical Center Richardson/Plano Richardson TX United States","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070710024","display_name":"Amaal Jilani Starling","orcid":"https://orcid.org/0000-0003-1334-1157","observed_orcids":["https://orcid.org/0000-0003-1334-1157"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amaal Starling","raw_affiliation_strings":["Mayo Clinic Scottsdale AZ United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Scottsdale AZ United States","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108076630","display_name":"Stephen David Silberstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Silberstein","raw_affiliation_strings":["Thomas Jefferson University Philadelphia PA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thomas Jefferson University Philadelphia PA United States","institution_ids":["https://openalex.org/I149251103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110013391","display_name":"Yanchen Zhou","orcid":"https://orcid.org/0000-0002-5245-0519","observed_orcids":["https://orcid.org/0000-0002-5245-0519"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanchen Zhou","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108599801","display_name":"Marie\u2010Louise Trotman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marie-Louise Trotman","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089710591","display_name":"Fei Xue","orcid":"https://orcid.org/0000-0001-7047-8497","observed_orcids":["https://orcid.org/0000-0001-7047-8497"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fei Xue","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008258554","display_name":"Farhad Sahebkar","orcid":"https://orcid.org/0000-0002-7748-7836","observed_orcids":["https://orcid.org/0000-0002-7748-7836"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Sahebkar-Moghaddam","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002736298","display_name":"Hern\u00e0n Picard","orcid":"https://orcid.org/0000-0002-8912-7539","observed_orcids":["https://orcid.org/0000-0002-8912-7539"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hernan Picard","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113649048","display_name":"Daniel D. Mikol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Mikol","raw_affiliation_strings":["Amgen Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.1791,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.77708712,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"90","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erenumab","display_name":"erenumab","score":0.9269999861717224},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7829999923706055},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9549999833106995},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.972000002861023},{"id":"https://openalex.org/keywords/cgrp-receptor-monoclonal-antibody","display_name":"CGRP receptor monoclonal antibody","score":0.7599999904632568},{"id":"https://openalex.org/keywords/pooled-analysis","display_name":"pooled analysis","score":0.4410000145435333}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.8250957727432251},{"id":"https://openalex.org/C2778541695","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Migraine","level":2,"score":0.749897301197052},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6888744831085205},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5697444081306458},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.49831438064575195},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3893657922744751},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2207944691181183},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.14413133263587952},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.061982303857803345},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.90.15_supplement.p4.098","doi":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.p4.098","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8100000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4221028150","https://openalex.org/W4389367604","https://openalex.org/W4308954661","https://openalex.org/W4220660536","https://openalex.org/W4389368800","https://openalex.org/W4246825671","https://openalex.org/W2770965214","https://openalex.org/W2917033428","https://openalex.org/W4389464261","https://openalex.org/W2885914247"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"determine":[2,101],"the":[3,23,29,102,118,122,180,209,252,255,293,516,570,604],"frequency":[4],"of":[5,11,28,50,104,115,121,141,158,230,257,266,518,520,572,574,606,608],"occurrence":[6,280],"and":[7,26,110,144,190,219,240,285,402,431,435],"potential":[8],"clinical":[9,63,290],"impact":[10,22,103,229,291],"anti-erenumab":[12,84,105,231,275],"antibodies.":[13],"Background:":[14],"Anti-drug":[15],"antibodies,":[16],"commonly":[17],"reported":[18],"with":[19,129,147,179,208,264,324,350,376,456,477,506,540,560,594],"biologics,":[20],"may":[21],"efficacy,":[24,108],"safety,":[25,109,234],"pharmacokinetics":[27],"drug.":[30],"Erenumab":[31],"is":[32],"a":[33,47,278,316,342,368,448,469,498,532,552,586],"fully":[34],"human":[35],"anti-CGRP":[36],"receptor":[37],"antibody":[38],"in":[39,170,187,194,199,216,223,235,259,297,486],"development":[40],"for":[41,77,83,92,312,338,364,444,465,494,513,528,548,567,582,601],"migraine":[42,78,172,201],"prevention.":[43,79],"Here":[44],"we":[45],"report":[46],"pooled":[48,273],"analysis":[49],"erenumab":[51,76,258],"immunogenicity.":[52],"Design/Methods:":[53],"Data":[54],"were":[55,90,98,137],"obtained":[56],"from":[57,174,203,379,411,417],"all":[58],"phase":[59,120],"2/phase":[60],"3":[61,133,178],"placebo-controlled":[62,124],"trials":[64,125],"(NCT01952574,":[65],"NCT02066415":[66],"[and":[67],"open-label":[68],"extension":[69],"study,":[70],"NCT02174861],":[71],"NCT02456740,":[72],"NCT02483585)":[73],"that":[74],"evaluated":[75],"Serum":[80],"was":[81,126,183,212,227],"tested":[82,91],"binding":[85],"antibodies":[86,94,106,232,276],"(BAbs);":[87],"BAb-positive":[88,159,195,224,261],"samples":[89],"neutralizing":[93],"(NAbs).":[95],"Pooled":[96],"data":[97],"used":[99],"to":[100,162,176,205],"on":[107,233,271,292,315,341,367,447,468,497,515,531,551,569,585,603],"pharmacokinetics.":[111],"Results:":[112],"Subject":[113],"incidence":[114],"BAbs":[116],"during":[117],"double-blind":[119],"four":[123],"6.3%":[127],"(56/884)":[128],"70":[130],"mg":[131,149],"(of":[132],"NAb-positive":[134],"subjects,":[135],"2":[136],"NAb-negative":[138],"by":[139,165],"end":[140],"study":[142],"[EOS]),":[143],"2.6%":[145],"(13/504)":[146],"140":[148],"(0":[150],"NAb-positive).":[151],"With":[152],"continued":[153],"treatment,":[154],"more":[155],"than":[156],"50%":[157],"subjects":[160,189,218,262],"reverted":[161],"BAb-negative":[163,188,217,267],"status":[164],"EOS.":[166],"Mean":[167,197],"(SE)":[168],"change":[169,198],"monthly":[171,200],"days":[173,202],"baseline":[175,204],"month":[177,206],"70-mg/140-mg":[181,210],"dose":[182,211],"\u22123.2":[184,191,220],"(0.2)/\u22123.6":[185],"(0.2)":[186,215],"(0.7)/\u22124.1":[192],"(0.8)":[193],"subjects.":[196,225,268,299],"6":[207],"\u22123.5":[213],"(0.2)/\u22123.8":[214],"(0.9)/\u22125.2":[221],"(0.9)":[222],"There":[226],"no":[228,288],"particular,":[236],"injection-site":[237],"reactions,":[238],"hypersensitivity,":[239],"immune-related":[241],"disorders.":[242],"Despite":[243],"an":[244],"overall":[245],"lower":[246],"exposure":[247],"(35\u201340%,":[248],"week":[249],"12)":[250],"at":[251],"group":[253],"level,":[254],"concentrations":[256],"individual":[260],"overlapped":[263],"those":[265],"Conclusions:":[269],"Based":[270],"this":[272],"analysis,":[274],"have":[277],"low":[279],"rate,":[281,284],"high":[282],"reversion":[283],"most":[286],"importantly,":[287],"appreciable":[289],"efficacy":[294],"or":[295,321,347,373,453,474,503,537,557,591],"safety":[296],"erenumab-treated":[298],"Study":[300],"Supported":[301],"by:":[302],"Amgen":[303,457],"Inc.":[304,458],"Disclosure:":[305],"Dr.":[306,332,358,405,438,459,479,488,508,522,542,562,576,596],"Vargas":[307],"has":[308,334,360,407,440,461,490,510,524,544,564,578,598],"received":[309,335,361,408,441,462,491,511,525,545,565,579,599],"personal":[310,336,362,442,463,492,526,546,580],"compensation":[311,337,363,443,464,493,512,527,547,566,581,600],"consulting,":[313,339,365,445,466,495,529,549,583],"serving":[314,340,366,446,467,496,514,530,550,568,584,602],"scientific":[317,343,369,449,470,499,533,553,587],"advisory":[318,344,370,450,471,500,534,554,588],"board,":[319,345,371,451,472,501,535,555,589],"speaking,":[320,346,372,452,473,502,536,556,590],"other":[322,348,374,454,475,504,538,558,592],"activities":[323,349,375,455,476,505,539,559,593],"Amgen,":[325,352],"Alder,":[326,351],"Allergan,":[327,382,418],"Avanir,":[328],"Pernix,":[329],"Teva,":[330],"Lilly.":[331],"Starling":[333],"Eli":[353,429],"Lilly":[354,430],"&":[355],"Company,":[356],"eNeura.":[357],"Silberstein":[359,406],"Receives":[377],"honoraria":[378],"Alder":[380],"Biopharmaceuticals;":[381],"Inc.;":[383,387,397,401,419,423,426],"Amgen;":[384,420],"Avanir":[385],"Pharmaceuticals,":[386,422],"eNeura;":[388],"ElectroCore":[389,424],"Medical,":[390,425],"LLC;":[391,395],"Labrys":[392,427],"Biologics;":[393,428],"Medscape,":[394],"Medtronic,":[396],"Neuralieve;":[398],"NINDS;":[399],"Pfizer,":[400],"Teva":[403],"Pharmaceuticals.":[404],"research":[409,415],"support":[410,416],"His":[412],"employer":[413],"receives":[414],"Cumberland":[421],"Company;":[432],"Merz":[433],"Pharmaceuticals;":[434],"Troy":[436],"Healthcare.":[437],"Zhou":[439],"Trotman":[460,480],"Amgen.":[478,487,507,521,541,561,575,595,609],"holds":[481],"stock":[482,484],"and/or":[483],"options":[485],"Xue":[489,509],"Board":[517,571,605],"Directors":[519,573,607],"Sahebkar-Moghaddam":[523],"Picard":[543,563],"Mikol":[577,597]},"counts_by_year":[{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2}],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2018-06-01T00:00:00"}